China Orders Additional Stockpile Of Sinovac Biotech’s Bird Flu Vaccine
This article was originally published in PharmAsia News
Executive Summary
China's Sinovac Biotech has been asked to step up production of its Panflu vaccine against the epidemic strain of the H5N1 virus in case of a bird flu epidemic. The State FDA said the addition to the current stockpile was sparked by eight cases of bird flu since December, five of them fatal. A spokeswoman said the situation was serious and that her agency also had initiated a program to inspect as it is produced so there are no delays if an outbreak occurs. Sinovac received clearance for Panflu last April for vaccinating humans ages 18 to 60. (Click here for more
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.